USNA:NYSEUSANA Health Sciences, Inc. Analysis

USANA is trading at $19.46, comfortably above its 20‑day SMA of 19.21 but below the 200‑day SMA of 22.59, indicating a short‑term pullback within a longer‑term downtrend. The RSI sits at 53.9, suggesting neutral momentum, while the MACD line (+0.266) remains just above its signal (+0.255), providing a modest bullish tilt. The stock is perched near the identified support level of $17.72 and faces resistance around $21.00, with a recent earnings surprise of $0.61 per share beating the consensus estimate of $0.44. Valuation metrics are compelling: a trailing PE of 38.9 contrasts sharply with a forward PE of 7.0, price‑to‑book is only 0.66, and price‑to‑sales sits at 0.39, yielding an upside potential of roughly 100 % versus the consensus target of $39. The company’s gross margin remains robust at 77.6 %, though operating and net margins are thin (5.5 % and 0.96 % respectively) and revenue growth is flat at 0.3 %. Financially, USANA carries modest debt ($14 M) against a cash pile of $163 M, resulting in a low debt‑to‑equity ratio, but free cash flow is currently reported as zero, highlighting cash conversion concerns. Volatility is high at 43.5 % over the past 30 days and beta exceeds 1.3, indicating sensitivity to market swings. The “Extreme Greed” sentiment on the Fear‑Greed Index (90.9) reflects strong investor appetite, yet the sector—Consumer Defensive—typically moderates downside risk. Overall, the stock appears undervalued with significant upside, but the combination of high volatility, modest profitability, and execution risk suggests a cautious stance.